Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061

Antiviral Therapy

Volumn 11, Issue 3, 2006, Pages 371-376

  Herrmann, Eva ^a   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a   Hinrichsen, Holger ^b   Benhamou, Yves ^c   Manns, Michael P ^d   Reiser, Markus ^e   Reesink, Henk ^f   Calleja, José L ^g   Forns, Xavier ^h   Steinmann, Gerhard G ⁱ   Nehmiz, Gerhard ⁱ  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CILUPREVIR; SERINE PROTEINASE INHIBITOR;

ARTICLE; CELL LOSS; FIBROSIS; HEPATITIS C; LIVER CIRRHOSIS; MICROBIAL KINETICS; PRIORITY JOURNAL; VIRUS INHIBITION;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CARBAMATES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KINETICS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; QUINOLINES; RNA, VIRAL; SERINE PROTEINASE INHIBITORS; THIAZOLES;

EID: 33744723134     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282:103-107.
2. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182:28-35.
3. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-1447.
4. Colombatto P, Civitano L, Oliveri F, et al. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 2003; 8:519-530.
5. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358.
6. Ribeiro RM, Layden-Almer J, Powers KA, Layden TJ, Perelson AS. Dynamics of alanine aminotransferase during hepatitis C virus treatment. Hepatology 2003; 38:509-517.
7. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924.
8. Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S. Viral Kinetics during antiviral therapy in Patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40:1442-1449.
9. Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Two days of oral treatment with BILN 2061, a HCV serine protease inhibitor, in patients with genotype 1 hepatitis C. Gastroenterology 2004; 127:1347-1355.
10. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32:818-823.
11. Beld M, Sentjens R, Rebers S, et al. Performance of the new bayer versant HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV monitor, version 2.0, assay. J Clin Microbiol 2002; 40:788-793.
12. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426:186-189.
13. Karino Y, Toyota J, Sugawara M, et al. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2003; 18:404-410.
14. Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35:930-936.
15. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN 2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005; 41:832-835.
16. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-17514.
17. Wodarz D, Lloyd AL. Immune responses and the emergence of drug-resistant virus strains in vivo. Proc Biol Sci 2004; 271:1101-1109.
18. Bonhoeffer S, Barbour AD, De Boer RJ. Procedures for reliable estimation of viral fitness from time-series data. Proc Biol Sci 2002; 269:1887-1893.